PapersPMID:38844675
The Effect of Palmitoylethanolamide (PEA) on Skeletal Muscle Hypertrophy, Strength, and Power in Response to Resistance Training in Healthy Active Adults: A Double-Blind Randomized Control Trial.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 48 participants · 8 weeks
- Dose studied, every finding
- Levagen+ 175 mg capsule (not less than 150 mg PEA) twice daily, oral, 8 weeks
No finding here moved its endpoint.
What did not
How to read these marks →“Lean mass increased by 2.0 ± 2.0% and 2.4 ± 2.1% in the PEA and PLA groups respectively, with no significant differences between groups (ITT: p = 0.38; PP: p = 0.39; Table 2; Fig. 3C).”
- Interests
- Industry funded
- Population
- Healthy, untrained, recreationally active adults aged 18-35 y; both arms did the same supervised 8-week resistance training programme with a standardised pre-workout snack and a post-session protein beverage; placebo was maltodextrin; intention-to-treat analysis
- No detected effect on body mass
moderate
“Body mass increased in both groups over the 8 weeks (PEA: 0.6 ± 1.4 kg; PLA: 1.0 ± 1.8 kg), with no significant difference between groups (Table 2; Fig. 3B).”
- Interests
- Industry funded
- Population
- Healthy, untrained, recreationally active adults aged 18-35 y; both arms did the same supervised 8-week resistance training programme; placebo was maltodextrin; intention-to-treat analysis
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- healthy, recreationally active, untrained adults undergoing 8 weeks of resistance training
- Participants
- 52
- Comparator
- placebo
- Duration
- 56 days
- Endpoints measured
- 77